Michael Brooks - Syneos Health Chief Officer
| SYNHDelisted Stock | USD 42.31 0.07 0.17% |
Insider
Michael Brooks is Chief Officer of Syneos Health
| Age | 49 |
| Phone | 919 876 9300 |
| Web | https://www.syneoshealth.com |
Michael Brooks Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Brooks against Syneos Health stock is an integral part of due diligence when investing in Syneos Health. Michael Brooks insider activity provides valuable insight into whether Syneos Health is net buyers or sellers over its current business cycle. Note, Syneos Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Syneos Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Brooks over six months ago Disposition of 1536 shares by Michael Brooks of LKQ at 57.3 subject to Rule 16b-3 | ||
Michael Brooks over six months ago Disposition of 1472 shares by Michael Brooks of LKQ at 51.986 subject to Rule 16b-3 |
Syneos Health Management Efficiency
The company has return on total asset (ROA) of 0.0263 % which means that it generated a profit of $0.0263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0209 %, meaning that it created $0.0209 on every $100 dollars invested by stockholders. Syneos Health's management efficiency ratios could be used to measure how well Syneos Health manages its routine affairs as well as how well it operates its assets and liabilities.Syneos Health currently holds 2.9 B in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. Syneos Health has a current ratio of 1.08, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about Syneos Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexander Dimitrief | Sotera Health Co | 65 | |
| Jeffrey Spaeder | IQVIA Holdings | N/A | |
| Natalie Munk | Myriad Genetics | 43 | |
| Oliver Wittorf | Mettler Toledo International | N/A | |
| Richard Wong | Mettler Toledo International | 59 | |
| Kevin Haas | Myriad Genetics | 38 | |
| MPH MD | Laboratory of | 48 | |
| Dr MBA | ICON PLC | 64 | |
| Clivetty Martinez | Myriad Genetics | N/A | |
| Dale Muzzey | Myriad Genetics | 44 | |
| Mark Schroeder | Laboratory of | 63 | |
| Daniel OLeary | Medpace Holdings | N/A | |
| Paul MD | Laboratory of | 62 | |
| Lehmann JD | Sotera Health Co | 56 | |
| Amy Summy | Laboratory of | 58 | |
| Kevin Brady | Medpace Holdings | 50 | |
| Flavia Pease | Charles River Laboratories | 51 | |
| Robert Hauzie | Sotera Health Co | N/A | |
| Dana Snr | ICON PLC | N/A | |
| Victoria Creamer | Charles River Laboratories | 54 | |
| MD Frcp | Aclaris Therapeutics | 63 | |
Management Performance
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 |
Syneos Health Leadership Team
Elected by the shareholders, the Syneos Health's board of directors comprises two types of representatives: Syneos Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syneos. The board's role is to monitor Syneos Health's management team and ensure that shareholders' interests are well served. Syneos Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syneos Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Meggs, Interim CFO, Executive Vice President | ||
| Jonathan Olefson, General Counsel, Corporate Secretary | ||
| Michael Brooks, Chief Officer | ||
| Judith MD, Chief Officer | ||
| Alistair Macdonald, CEO, Director | ||
| Ronnie Speight, Vice President Investor Relations | ||
| Baba Shetty, Pres Solutions | ||
| Michelle Keefe, CEO Director | ||
| Larry Pickett, Chief Officer | ||
| Donna Kralowetz, Sr Officer |
Syneos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syneos Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 7.23 B | |||
| Shares Outstanding | 103.72 M | |||
| Shares Owned By Insiders | 0.48 % | |||
| Shares Owned By Institutions | 94.74 % | |||
| Number Of Shares Shorted | 6.76 M | |||
| Price To Earning | 18.05 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Syneos Stock
If you are still planning to invest in Syneos Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syneos Health's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |